 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Oct 10, 2022 |
| Title |
Histological subtypes drive distinct prognostic immune signatures in classical Hodgkin lymphoma. |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Classical Hodgkin lymphoma (cHL) is a highly curable disease, with about 80% of patients cured using standard first-line chemotherapy. However, outcomes for relapsed/refractory patients re-main unfavorable and there is a critical lack of predictive biomarkers for early identification of these patients who may benefit from new therapeutic strategies. Here we evaluated the dynamic expression of 571 immune-related genes in a cohort of 42 cHL using NanoString technology. We identified a 19-genes immune signature predictive of relapse at the time of diagnosis, which was found to be strongly dependent on histological subtype. Moreover, comparative analyses be-tween paired diagnostic/relapsed biopsies of nodular sclerosis cHL showed 134 differentially expressed genes, highlighting an immune contexture shift at relapse not found in the mixed-cellularity subtype. Overall, these results strongly suggest that the predictive value of immune signature in cHL is influenced by histological subtype, a criterion that should be con-sidered when assessing new immunotherapy strategies.
|
| |
|
| Overall design |
Sixty-six formalin fixed paraffin embedded (FFPE) cHL biopsies at diagnosis and/or at relapse were obtained from a total of 42 patients, including 30 r/r cHL patients and 12 non-r/r cHL patients. Thirty-five FFPE samples were available at diagnosis (n= 12 non-r/r cHL and n=23 r/r cHL) and FFPE paired diagnosis and relapse biopsies were available for 22/30 r/r cHL patients. Nodular sclerosis subtype was the most represented histological subtype in our series (n=24/42, 57.1%) followed by the mixed-cellularity subtype (n=15/42, 35.7%). Only two patients presented a lymphocyte-rich pattern (4.8%), and one patient displayed a lymphocyte-depleted pattern (2.4%). The average age at diagnosis of r/r patients was 30 years (ranging from 15y to 83y) and that of non-r/r patients was 31 years (ranging from 23y to 58y). Less than 25% (n=9/39) of cases were Epstein-Barr virus (EBV) positive. EBV status was unknown for 3 cases. Thirty-two (78%) patients, including 20/30 r/r patients and 12/12 non-r/r patients, had extensive disease at diagnosis (Ann Arbor stage III-IV). Of the 40 assessable patients, 30.9% (n=13) were treated with bleomycin, etoposide, doxoru-bicin, cyclophosphamide, vincristine, procarbazine and prednisone (BEACOPP) and 57.1% (n=24) received doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD). The 3 remaining patients received alternative chemotherapy
|
| |
|
| Contributor(s) |
Lamaison C, Syrykh C |
| Citation(s) |
36230815 |
| |
| Submission date |
Sep 08, 2022 |
| Last update date |
Oct 28, 2022 |
| Contact name |
Pauline Gravelle |
| E-mail(s) |
pauline.gravelle@inserm.fr
|
| Organization name |
IUCT-ONCOPOLE
|
| Department |
Anatomy-Pathology
|
| Street address |
1 Avenue Irène Joliot Curie
|
| City |
TOULOUSE |
| ZIP/Postal code |
31059 |
| Country |
France |
| |
|
| Platforms (1) |
| GPL32643 |
Nanostring nCounter Human Immunology V2 with panel plus |
|
| Samples (66)
|
| GSM6560834 |
cHL biopsy, 9D |
| GSM6560835 |
cHL biopsy, 9R |
| GSM6560836 |
cHL biopsy, 11R |
| GSM6560837 |
cHL biopsy, 5D |
| GSM6560838 |
cHL biopsy, 5R |
| GSM6560839 |
cHL biopsy, 14D |
| GSM6560840 |
cHL biopsy, 14R |
| GSM6560841 |
cHL biopsy, 36D |
| GSM6560842 |
cHL biopsy, 37D |
| GSM6560843 |
cHL biopsy, 32D |
| GSM6560844 |
cHL biopsy, 38D |
| GSM6560845 |
cHL biopsy, 31D |
| GSM6560846 |
cHL biopsy, 33D |
| GSM6560847 |
cHL biopsy, 39D |
| GSM6560848 |
cHL biopsy, 40D |
| GSM6560849 |
cHL biopsy, 34D |
| GSM6560850 |
cHL biopsy, 41D |
| GSM6560851 |
cHL biopsy, 42D |
| GSM6560852 |
cHL biopsy, 35D |
| GSM6560853 |
cHL biopsy, 11D |
| GSM6560854 |
cHL biopsy, 8R |
| GSM6560855 |
cHL biopsy, 17D |
| GSM6560856 |
cHL biopsy, 17R |
| GSM6560857 |
cHL biopsy, 21D |
| GSM6560858 |
cHL biopsy, 21R |
| GSM6560859 |
cHL biopsy, 1D |
| GSM6560860 |
cHL biopsy, 1R |
| GSM6560861 |
cHL biopsy, 2D |
| GSM6560862 |
cHL biopsy, 2R |
| GSM6560863 |
cHL biopsy, 20D |
| GSM6560864 |
cHL biopsy, 20R |
| GSM6560865 |
cHL biopsy, 18D |
| GSM6560866 |
cHL biopsy, 4D |
| GSM6560867 |
cHL biopsy, 22D |
| GSM6560868 |
cHL biopsy, 16D |
| GSM6560869 |
cHL biopsy, 27R |
| GSM6560870 |
cHL biopsy, 6D |
| GSM6560871 |
cHL biopsy, 4R |
| GSM6560872 |
cHL biopsy, 22R |
| GSM6560873 |
cHL biopsy, 16R |
| GSM6560874 |
cHL biopsy, 8D |
| GSM6560875 |
cHL biopsy, 18R |
| GSM6560876 |
cHL biopsy, 13R |
| GSM6560877 |
cHL biopsy, 24R |
| GSM6560878 |
cHL biopsy, 25R |
| GSM6560879 |
cHL biopsy, 23D |
| GSM6560880 |
cHL biopsy, 3D |
| GSM6560881 |
cHL biopsy, 12D |
| GSM6560882 |
cHL biopsy, 19D |
| GSM6560883 |
cHL biopsy, 19R |
| GSM6560884 |
cHL biopsy, 26R |
| GSM6560885 |
cHL biopsy, 10R |
| GSM6560886 |
cHL biopsy, 6R |
| GSM6560887 |
cHL biopsy, 13D |
| GSM6560888 |
cHL biopsy, 10D |
| GSM6560889 |
cHL biopsy, 12R |
| GSM6560890 |
cHL biopsy, 19R2 |
| GSM6560891 |
cHL biopsy, 19R3 |
| GSM6560892 |
cHL biopsy, 28R |
| GSM6560893 |
cHL biopsy, 29R |
| GSM6560894 |
cHL biopsy, 3R |
| GSM6560895 |
cHL biopsy, 30R |
| GSM6560896 |
cHL biopsy, 7D |
|
| Relations |
| BioProject |
PRJNA877867 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE212902_RAW.tar |
480.0 Kb |
(http)(custom) |
TAR (of RCC) |
| Processed data included within Sample table |
|
|
|
|
 |
Less...
More...